Healthcare provider profile · identity verified

Andres Bustamante

Internal Medicine · CHULA VISTA, CA · NPI 1720199227

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	653	239
Amlodipine Besylate	Amlodipine Besylate	459	161
Rosuvastatin Calcium	Rosuvastatin Calcium	448	168
Losartan Potassium	Losartan Potassium	360	124
Levothyroxine Sodium	Levothyroxine Sodium	341	109
Metformin Hcl Er	Metformin Hcl	274	89
Metformin Hcl	Metformin Hcl	248	90
Tamsulosin Hcl	Tamsulosin Hcl	220	69
Omeprazole	Omeprazole	205	85
Glipizide	Glipizide	200	67
Lisinopril	Lisinopril	197	78
Metoprolol Tartrate	Metoprolol Tartrate	191	63
Meloxicam	Meloxicam	187	83
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	184	33
Potassium Chloride	Potassium Chloride	177	74
Jardiance	Empagliflozin	175	63
Furosemide	Furosemide	166	64
Alendronate Sodium	Alendronate Sodium	161	61
Hydralazine Hcl	Hydralazine Hcl	157	56
Ezetimibe	Ezetimibe	130	48
Pantoprazole Sodium	Pantoprazole Sodium	130	47
Trazodone Hcl	Trazodone Hcl	121	47
Finasteride	Finasteride	109	37
Tramadol Hcl	Tramadol Hcl	104	23
Atenolol	Atenolol	103	36
Gabapentin	Gabapentin	103	39
Albuterol Sulfate Hfa	Albuterol Sulfate	97	46
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	93	36
Eliquis	Apixaban	87	23
Pioglitazone Hcl	Pioglitazone Hcl	84	30
Pradaxa	Dabigatran Etexilate Mesylate	84	28
Simvastatin	Simvastatin	77	32
Hydrochlorothiazide	Hydrochlorothiazide	75	31
Metoprolol Succinate	Metoprolol Succinate	74	27
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	72	29
Allopurinol	Allopurinol	71	27
Sertraline Hcl	Sertraline Hcl	65	26
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	61	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	60	23
Humulin N	Insulin Nph Human Isophane	59	24
Terazosin Hcl	Terazosin Hcl	57	23
Carvedilol	Carvedilol	56	18
Clopidogrel	Clopidogrel Bisulfate	56	22
Famotidine	Famotidine	54	23
Myrbetriq	Mirabegron	53	21
Ondansetron Odt	Ondansetron	53	33
Propranolol Hcl	Propranolol Hcl	53	20
Spiriva Respimat	Tiotropium Bromide	52	17
Victoza 2-Pak	Liraglutide	52	15
Hydrocortisone	Hydrocortisone	51	26
Estradiol	Estradiol	48	26
Spironolactone	Spironolactone	45	16
Donepezil Hcl	Donepezil Hcl	44	12
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	44	18
Humulin R	Insulin Regular, Human	42	14
Mirtazapine	Mirtazapine	42	23
Doxycycline Monohydrate	Doxycycline Monohydrate	40	35
Fluocinonide	Fluocinonide	40	19
Fluoxetine Hcl	Fluoxetine Hcl	37	11
Liraglutide	Liraglutide	37	19
Sitagliptin	Sitagliptin	37	23
Wixela Inhub	Fluticasone Propion/Salmeterol	37	15
Arexvy	Rsvpref3 Antigen/As01e/Pf	35	34
Humulin N Kwikpen	Insulin Nph Human Isophane	35	13
Triamcinolone Acetonide	Triamcinolone Acetonide	35	19
Nitroglycerin	Nitroglycerin	34	22
Fluticasone Propionate	Fluticasone Propionate	33	18
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	33	suppressed
Mirabegron Er	Mirabegron	32	16
Ozempic	Semaglutide	32	11
Midodrine Hcl	Midodrine Hcl	31	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	30	suppressed
Cyclosporine	Cyclosporine	29	20
Fenofibrate	Fenofibrate	29	suppressed
Pregabalin	Pregabalin	27	11
Breyna	Budesonide/Formoterol Fumarate	26	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Latanoprost	Latanoprost	26	suppressed
Memantine Hcl	Memantine Hcl	26	suppressed
Prednisone	Prednisone	26	21
Colchicine	Colchicine	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	11
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	25	22
Alprazolam	Alprazolam	24	suppressed
Montelukast Sodium	Montelukast Sodium	24	suppressed
Naloxone Hcl	Naloxone Hcl	24	18
Humalog Kwikpen U-100	Insulin Lispro	23	suppressed
Ibuprofen	Ibuprofen	23	15
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	22	15
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Clonidine Hcl	Clonidine Hcl	21	suppressed
Rivastigmine	Rivastigmine	21	suppressed
Tradjenta	Linagliptin	21	11
Baclofen	Baclofen	20	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	20	suppressed
Lactulose	Lactulose	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Tacrolimus	Tacrolimus	17	11
Amoxicillin	Amoxicillin	16	suppressed
Potassium Citrate Er	Potassium Citrate	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Amiodarone Hcl	Amiodarone Hcl	15	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	15	suppressed
Timolol Maleate	Timolol Maleate	15	suppressed
Varenicline Tartrate	Varenicline Tartrate	15	suppressed
Lovastatin	Lovastatin	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	13	suppressed
Buspirone Hcl	Buspirone Hcl	12	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	12	suppressed
Bumetanide	Bumetanide	11	suppressed
Cephalexin	Cephalexin	11	11
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	11
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error